Welcome to our dedicated page for Tg Therapeutics SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TG Therapeutics' SEC filings document a commercial-stage biotechnology issuer whose common stock trades on the Nasdaq Capital Market under TGTX. The filings cover operating results and financial condition, BRIUMVI product revenue and revenue guidance, license, royalty and other commercialization revenue, and research and development spending tied to its B-cell disease pipeline.
Material-event filings also record capital-structure actions such as senior secured credit financing, repayment of prior term loans, and related borrowing terms. Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting matters, and governance practices for the public company.
TG Therapeutics director Laurence N. Charney reported two bona fide gifts of the company's Common Stock to his children. He gifted 30,000 shares on 01/28/2026 and 13,197 shares on 01/29/2026, both at a reported price of $0 per share.
After these gifts, Charney beneficially owned 192,887 shares and then 179,690 shares of Common Stock, held directly. This amount includes shares of restricted stock that vest over various time periods. The gifts were structured so he does not retain beneficial ownership or pecuniary interest in the transferred shares.
TG Therapeutics, Inc. filed a current report to share that it has released a press release providing preliminary fourth quarter and full year 2025 net product revenue, along with 2026 revenue guidance and anticipated development milestones.
The company furnished this information under a Regulation FD disclosure, attaching the full press release as Exhibit 99.1. The exhibit contains the detailed financial figures and milestone timelines, while the report itself mainly documents that this information has been made publicly available.
TG Therapeutics reported that CEO and director Michael S. Weiss received a grant of 622,000 shares of restricted common stock on January 8, 2026. The shares were granted at a price of $0 per share and are subject to performance-based vesting. They will vest on the first anniversary of the date on which the company’s total shareholder return first exceeds the return of the Nasdaq Biotechnology Index over a 3-, 5-, 7-, or 9-year period. Following this award, Weiss beneficially owned 9,778,086 shares of common stock, including other restricted shares that vest over various time periods.
TG Therapeutics CFO Sean A. Power reported an equity grant. On 01/08/2026 he was awarded 90,000 shares of TG Therapeutics common stock at a price of $0 per share, reported as an acquisition of non-derivative securities.
These are restricted shares, with one quarter scheduled to vest on each of 01/01/2027, 01/01/2028, 01/01/2029, and 01/01/2030. After this grant, he beneficially owns 798,111 shares of common stock, including restricted shares that vest over various time periods, all held directly.
TG Therapeutics director reports stock sale to cover taxes
A director of TG Therapeutics, Inc. (TGTX), Yann Echelard, reported a sale of company common stock. On 11/24/2025, 5,000 shares of TG Therapeutics common stock were sold at a price of $32.57 per share, as shown in Table I of the filing. The explanation states that these shares were sold by the company’s restricted stock administrator to satisfy Mr. Echelard’s income tax obligations.
After this transaction, Mr. Echelard beneficially owned 223,816 shares of TG Therapeutics common stock in direct form, which includes shares of restricted common stock that vest over various time periods.
TG Therapeutics (TGTX) CEO and director Michael S. Weiss filed a Form 4 reporting non-sale transfers of common stock. On 11/05/2025, he reported a distribution of 3,865,126 shares upon termination of the Michael Sean Weiss 2022 Grantor Retained Annuity Trust to irrevocable trusts for the benefit of his children, and a transfer of 803,717 shares to The Weiss Family and Descendants Trust. Both transactions were coded “G” and priced at $0 per share.
Following these transactions, Mr. Weiss beneficially owned 9,156,086 shares of TG Therapeutics common stock. The filing notes that this total includes shares of restricted stock that vest over various time periods.
TG Therapeutics reported Q3 2025 results highlighted by strong BRIUMVI sales and a large tax benefit. Total revenue was $161.7M, driven by product revenue of $159.3M. Operating income reached $29.4M, and net income was $390.9M, reflecting an income tax benefit of $365.0M. Diluted EPS was $2.43.
For the first nine months, total revenue was $423.7M, including $417.8M of product revenue, with $6.4M from BRIUMVI sales to Neuraxpharm. Accounts receivable were $265.4M and inventories $147.0M as of Sep 30, 2025. Cash, cash equivalents and investment securities totaled $178.3M, while loan payable (non‑current) was $245.3M.
The company completed its $100M share repurchase program, buying 2,782,545 shares for $78.2M in Q3, and authorized a new $100M program. There were 158,759,451 common shares outstanding as of Oct 31, 2025.
TG Therapeutics, Inc. filed a current report to note that it has released its financial results. On November 3, 2025, the company issued a press release covering its results of operations for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1. The information about these quarterly and year-to-date results is being furnished, not filed, which means it is not automatically subject to certain liability provisions or incorporated into other SEC filings unless specifically referenced.
TG Therapeutics (TGTX) notice of proposed sale reports an insider intends to sell 20,852 common shares through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $672,232.59. These shares represent approximately 0.013% of the reported 158,665,613 shares outstanding and were acquired on 06/22/2023 by restricted stock vesting as compensation.
The filing lists no securities sold in the past three months and specifies the proposed sale date as 09/11/2025. The filer affirms they are not aware of any undisclosed material adverse information about the issuer. This is a routine Rule 144 disclosure showing a planned disposition of vested equity awarded as compensation.
TG Therapeutics, Inc. filed a Form S-8 registration statement on August 8, 2025 to register securities under the TG Therapeutics, Inc. 2022 Incentive Plan. The filing incorporates by reference the company’s Annual Report for the fiscal year ended December 31, 2024 (filed March 3, 2025) and subsequent Exchange Act reports, and lists exhibits including the 2022 Incentive Plan and two amendments, legal opinion of DLA Piper LLP and KPMG consent.
The filing indicates the company is a large accelerated filer, names Sean Power as agent for service, and describes charter and bylaw provisions limiting director liability (excluding liabilities under federal securities laws). Item 4 is marked Not applicable.